Release date: 2015-08-26
In a recent report, foreign business intelligence agency GBI Research pointed out that the global market for multiple myeloma therapy will grow from $7.3 billion in 2014 to $8.9 billion in 2021, with a compound annual growth rate (CAGR). Moderate, 4.6%.
GBI Research reports that the growth of the multiple myeloma therapy market is mainly in the following eight regional markets, namely the United States, the United Kingdom, France, Germany, Italy, Spain, Japan, and Canada. The driving factors for growth are mainly population aging. Increasing the incidence of continual increase.
Drugs currently on the market, such as Celgene's Revlimid (lenalidomide), have annual sales of $4.9 billion. With the approval of new drugs, the market for multiple myeloma therapy will be complemented, providing patients with alternative improved therapies and, to a certain extent, promoting market growth in this therapeutic segment.
Promising drug candidates include late-stage oral drug ixazomib from Takeda, filanesib from American new drug research company ArraryBiopharma, elotuzumab from BMS/AbbVie, and daratumumab from Janssen.
Yasser Mushtaq, a senior analyst from GBI Research, said that although multiple myeloma is still incurable, there is a deeper understanding of its mechanisms at the level of cellular and molecular biology, driving research into innovative therapies in the therapeutic field. Progress has led to a significant increase in clinical outcomes.
Some drugs in the late development pipeline will not have a significant impact on the overall market, and some drugs have shown promising clinical trial results in a particular patient population, including elotuzumab from BMS/AbbVie and daratumumab from Janssen. These drugs are expected to provide patients with more choices in therapy. However, various market barriers (such as a limited number of target patients) will limit further growth in the multiple myeloma therapy market.
Mushtaq explained that on the one hand, multiple myeloma is identified as orphan disease because of its rarity, and the number of patients is limited to a certain extent, hindering the potential growth of the market in this field. On the other hand, expensive drug development costs have slowed the pace of pharmaceutical companies investing in this therapeutic area. However, the government's encouragement for the development of multiple myeloma drugs, drugs from other therapeutic areas for multiple myeloma, can promote the development of this therapeutic field to some extent.
Source: New Kangjie
Natural field As Health Care Ingredient manufacturers, Focus on the research and production of raw materials for male health products. The functions of these products are: 1. Enhance thyroid function 2. Reduce stress and Anti-anxiety 3. Helps the body detoxify 4. Improve memory and brain cell function 5. Stimulate the Improving immunity.
Eg:Pygeum Africanum extract can inhibite benign prostatic hypertrophy and cancer of the prostate.
Male & Female Health Extract,Male Health Care Ingredient,Female Health Ingredient,Female Health Extract
Xi'an Natural Field Bio-Technique Co., Ltd. , https://www.naturalnf.com